IDEAS home Printed from https://ideas.repec.org/r/eee/pubeco/v145y2017icp181-200.html

Innovation under regulatory uncertainty: Evidence from medical technology

Citations

Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
as


Cited by:

  1. Reypens, Lina & Bacq, Sophie & Milanov, Hana, 2021. "Beyond bricolage: Early-stage technology venture resource mobilization in resource-scarce contexts," Journal of Business Venturing, Elsevier, vol. 36(4).
  2. Ariel Dora Stern, 2022. "The Regulation of Medical AI: Policy Approaches, Data, and Innovation Incentives," NBER Working Papers 30639, National Bureau of Economic Research, Inc.
  3. Seokbeom Kwon & Jan Youtie & Alan Porter & Nils Newman, 2024. "How does regulatory uncertainty shape the innovation process? Evidence from the case of nanomedicine," The Journal of Technology Transfer, Springer, vol. 49(1), pages 262-302, February.
  4. Hermosilla, Manuel, 2024. "Regulating ethical experimentation: Impacts of the breakthrough therapy designation on drug R&D," Journal of Health Economics, Elsevier, vol. 94(C).
  5. Gamba, Simona & Magazzini, Laura & Pertile, Paolo, 2021. "R&D and market size: Who benefits from orphan drug legislation?," Journal of Health Economics, Elsevier, vol. 80(C).
  6. Ariel Dora Stern, 2022. "The Regulation of Medical AI: Policy Approaches, Data, and Innovation Incentives," NBER Chapters, in: The Economics of Artificial Intelligence: Health Care Challenges, pages 107-131, National Bureau of Economic Research, Inc.
  7. Dranove, David & Garthwaite, Craig & Heard, Christopher & Wu, Bingxiao, 2022. "The economics of medical procedure innovation," Journal of Health Economics, Elsevier, vol. 81(C).
  8. Yan Dong & Sining Song & Fan Zou, 2023. "Mobile Payment Services, Government Involvement, and Mobile Network Operator Performance," Manufacturing & Service Operations Management, INFORMS, vol. 25(6), pages 2002-2020, November.
  9. Massimo Florio & Simona Gamba, 2021. "Biomed Europa: After the coronavirus, a public infrastructure to overcome the pharmaceutical oligopoly," Annals of Public and Cooperative Economics, Wiley Blackwell, vol. 92(3), pages 387-409, September.
  10. Margaret K. Kyle, 2020. "The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals," Innovation Policy and the Economy, University of Chicago Press, vol. 20(1), pages 95-123.
  11. Matthew Grennan & Robert J. Town, 2020. "Regulating Innovation with Uncertain Quality: Information, Risk, and Access in Medical Devices," American Economic Review, American Economic Association, vol. 110(1), pages 120-161, January.
  12. Huiyan Zhang & Lee Branstetter & Raffaele Conti & Samir Mamadehussene, 2023. "Who gains and who loses from more information in technology markets? Evidence from the Sunshine Act," Strategic Management Journal, Wiley Blackwell, vol. 44(10), pages 2377-2412, October.
  13. Sofia Amaral-Garcia, 2020. "Medical Device Companies and Doctors: Do their Interactions Affect Medical Treatments ?," Working Papers ECARES 2020-18, ULB -- Universite Libre de Bruxelles.
  14. Ferriani, Simone & Lazerson, Mark H. & Lorenzoni, Gianni, 2020. "Anchor entrepreneurship and industry catalysis: The rise of the Italian Biomedical Valley," Research Policy, Elsevier, vol. 49(8).
  15. Matthew Grennan & Charu Gupta & Mara Lederman, 2018. "Firm Scope and Spillovers from New Product Innovation: Evidence from Medical Devices," NBER Working Papers 25183, National Bureau of Economic Research, Inc.
  16. Amaral-Garcia, S.;, 2022. "Medical Device Companies and Doctors: Do their interactions affect medical treatments?," Health, Econometrics and Data Group (HEDG) Working Papers 22/10, HEDG, c/o Department of Economics, University of York.
  17. Zhang, Jianhong & Jiang, Jiangang, 2024. "Investment deregulation and innovation performance of Chinese private firms," Journal of Financial Stability, Elsevier, vol. 70(C).
  18. Shatrov, Kosta & Blankart, Carl Rudolf, 2022. "After the four-year transition period: Is the European Union's Medical Device Regulation of 2017 likely to achieve its main goals?," Health Policy, Elsevier, vol. 126(12), pages 1233-1240.
  19. Dirk Dohse & Rajeev K. Goel & James W. Saunoris, 2023. "Patenting uncertainty and its impact on innovation: evidence from the United States," The Journal of Technology Transfer, Springer, vol. 48(5), pages 1839-1859, October.
  20. Ye, Qiaozhi & Huang, Ronghong & Tan, Kelvin Jui Keng, 2023. "Missing the boat: Regulatory approval delay and investment project outcomes," The British Accounting Review, Elsevier, vol. 55(6).
  21. Ziyi Zhao & Banghao Zhou, 2022. "Latecomers’ Isomorphic R&D Strategy and the Relationship With Performance: A Study on Chinese Pharmaceutical Firms," SAGE Open, , vol. 12(2), pages 21582440221, May.
  22. Gillner, Sandra & Blankart, Katharina Elisabeth & Bourgeois, Florence Tanya & Stern, Ariel Dora & Blankart, Carl Rudolf, 2024. "The challenges of regulatory pluralism," Health Policy, Elsevier, vol. 149(C).
  23. Fabian Grünwald & Tom Stargardt, 2024. "Harmonizing regulatory market approval of products with high safety requirements: Evidence from the European pharmaceutical market," Health Economics, John Wiley & Sons, Ltd., vol. 33(7), pages 1546-1564, July.
  24. Xiao, Fenglong, 2022. "Non-competes and innovation: Evidence from medical devices," Research Policy, Elsevier, vol. 51(6).
  25. Semjonova Nadezhda, 2020. "Economic Tendencies of the European and Latvian Medical Device Market," Economics and Business, Sciendo, vol. 34(1), pages 297-310, February.
  26. repec:osf:socarx:c8s3m_v1 is not listed on IDEAS
IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.